Back to News
Market Impact: 0.35
TriSalus Gets FDA Clearance For TriNav Advance For Liver Embolization; Overnight Stock Up 17%
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationProduct Launches
TriSalus Life Sciences received FDA 510(k) clearance for TriNav Advance, expanding its Pressure-Enabled Drug Delivery (PEDD) portfolio for liver embolization procedures. The clearance supports commercialization of the oncology-focused medical technology company's liver-directed treatment platform and is a positive catalyst for its product portfolio.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
strongly positive
Sentiment Score
0.55
Ticker Sentiment
TLSI0.78
More News
- CoreWeave seeks truce with Texas Governor-elect Hinojosa
- Street Calls of The Week
- Florida’s new property tax cuts could defund the police, fire fighters and EMS in small towns, threatening ‘rural dark ages,’ former GOP lawmaker says
- Asia Markets Brace for More AI Volatility
- Binance CFO exits days after catastrophic $6 billion crypto hack
- Paraguay’s ousted president charged over banking scandal